<DOC>
	<DOCNO>NCT00125827</DOCNO>
	<brief_summary>Clofarabine ( injection ) approve Food Drug Administration ( FDA ) treatment pediatric patient 1 21 year old relapse acute lymphoblastic leukemia ( ALL ) least 2 prior treatment regimen . This research study clofarabine give patient ( orally ) advance cancerous tumor cancerous tumor spread standard drug longer effective reliable effective treatment available . The purpose study find answer follow research question : 1 . What large dose oral clofarabine safely give daily 5 day follow 23 day rest repeat every 28 day ? 2 . What side effect clofarabine give schedule ? 3 . How much oral clofarabine blood specific time administration body get rid drug ? 4 . Will oral clofarabine help treat solid tumor cancer ?</brief_summary>
	<brief_title>Study Oral Clofarabine Administered Daily 5 Days Adult Patients With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Have pathologically confirm diagnosis solid tumor malignancy refractory conventional therapy therapy exists . Patients must measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Be great equal 18 year old . Must eligible therapy higher curative potential . ( NB : Where alternative therapy show prolong survival analogous population , therapy offer patient prior discuss study . ) Have Karnofsky Performance Status ( KPS ) great equal 70 . Have estimate life expectancy great equal 12 week . Be male nonpregnant , nonlactating female . Patients fertile must agree use effective barrier method birth control ( ie , latex condom , diaphragm , cervical cap , etc . ) avoid pregnancy . Have negative serum urine pregnancy test within 10 day study treatment ( patient female childbearing potential ) . Sign write informed consent form . Have adequate organ function indicate follow laboratory value , obtain within 2 week prior registration : A. ANC : great equal 1.5 × 10 ^9th/L ; B. Platelets : great equal 100 × 10 ^9th/L ; C.Serum bilirubin : le 2.0 mg/dL ; D. AST ALT : less 3 x ULN* without liver involvement OR le 5 x ULN liver involvement ; E. Serum creatinine : le equal 2.0 mg/dL . NOTE : ULN = Institutional Upper Limit Normal . Have receive previous treatment clofarabine . Have active , uncontrolled systemic infection consider opportunistic , life threatening , clinically significant time treatment . Are pregnant lactating . Have psychiatric disorder ( ) would interfere consent , study participation , followup . Have receive chemotherapy , major surgery , irradiation , whether conventional investigational , 28 day treatment study ( 42 day mitomycinC nitrosourea ) . Have recover acute toxicity previous therapy prior enrollment . Have severe concurrent disease , , judgment investigator , would make patient inappropriate entry study ( eg , uncontrolled severe insulindependent diabetes , uncontrolled hypertension , transient ischemic attack , uncontrolled symptomatic coronary artery disease , etc ) . Patients abnormal cardiac function consideration study participation discuss Medical Monitor prior enrollment . Have receive prior radiation therapy great equal 25 % bone marrow ( eg , whole pelvic irradiation allow ) recover acute side effect radiotherapy . Have symptomatic untreated central nervous system ( CNS ) metastases .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>CLO152</keyword>
	<keyword>Clolar</keyword>
</DOC>